0Y5F logo

Endo International LSE:0Y5F Stock Report

Last Price

US$0.0006

Market Cap

US$151.6k

7D

0%

1Y

-99.0%

Updated

03 May, 2024

Data

Company Financials

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

0Y5F Stock Overview

A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details

0Y5F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Endo Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Endo International
Historical stock prices
Current Share Price€0.0006
52 Week High€0.069
52 Week Low€0.0003
Beta0.80
1 Month Change100.00%
3 Month Change0%
1 Year Change-98.97%
3 Year Change-99.99%
5 Year Change-99.99%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

0Y5FGB PharmaceuticalsGB Market
7D0%-1.7%-2.6%
1Y-99.0%-3.5%2.4%

Return vs Industry: 0Y5F underperformed the UK Pharmaceuticals industry which returned 6.3% over the past year.

Return vs Market: 0Y5F underperformed the UK Market which returned 3.5% over the past year.

Price Volatility

Is 0Y5F's price volatile compared to industry and market?
0Y5F volatility
0Y5F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0Y5F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0Y5F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,931Blaise Colemanwww.endo.com

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.

Endo Inc. Fundamentals Summary

How do Endo International's earnings and revenue compare to its market cap?
0Y5F fundamental statistics
Market capUS$151.59k
Earnings (TTM)-US$2.45b
Revenue (TTM)US$2.01b

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0Y5F income statement (TTM)
RevenueUS$2.01b
Cost of RevenueUS$941.90m
Gross ProfitUS$1.07b
Other ExpensesUS$3.52b
Earnings-US$2.45b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-10.41
Gross Margin53.17%
Net Profit Margin-121.69%
Debt/Equity Ratio-123.5%

How did 0Y5F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/03 16:11
End of Day Share Price 2024/05/03 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research